<DOC>
	<DOCNO>NCT00135863</DOCNO>
	<brief_summary>Patients end stage renal disease ( ESRD ) use peritoneal dialysis Physioneal ( R ) ( Baxter A/S , Denmark ) allocate inject either placebo tinzaparin daily morning dialysis bag . Active medication , well placebo , add three month separate one month washout period . At begin end treatment period peritoneal equilibration test ( PE-tests ) , Kt/V , blood dialysate sample analyze . We , researcher Ribe County Hospital , set examine inflammation ( local systemic ) , nutrition ultrafiltration .</brief_summary>
	<brief_title>MesoHep II : Intraperitoneal Low Molecular Weight Heparin Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>End stage renal disease Peritoneal dialysis without complication minimum three month 18 year Informed consent Known coagulatory defect include anticoagulation therapy Known bleeding tendency Peritonitis within two month prior inclusion Pregnancy Breast feed Active infection Noninformed consent Allergy heparin prior heparin induce thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>